Drugs / TSI-GSD 200
TSI-GSD 200
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03609398 | Oct 2018 → Dec 2023 overdue | Rift valley fever | U.S. Army Medical Research and Development Command | Recruiting | No outcome recorded |
| Phase 2 | NCT00869713 | Sep 2009 → Feb 2019 | Rift valley fever | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 2 | NCT00584194 | Jun 2004 → May 2010 | Rift valley fever | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSI GSD 200 | “A Phase 2 Open Label Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated, Dried, TSI-GSD 200, Lot 7, Run 2, in Adult Subjects at Risk of Exposure to Rift...” NCT03609398 ↗3“Rift Valley Fever Vaccine, Inactivated, Dried (TSI GSD 200) will be administered in 1.0-mL doses SQ in the upper outer aspect of the arm.” NCT03609398 ↗ |
| Known as | Rift Valley Fever (RVF) Vaccine, Inactivated | “The primary objectives are to assess safety of Rift Valley Fever (RVF) Vaccine, Inactivated (TSI-GSD 200) and to assess immunogenicity of Rift Valley Fever (RVF) Vaccine,...” NCT00869713 ↗ |
| Known as | Rift Valley Fever Vaccine, Inactivated, Dried | “Long-Term Open-Label Primary Vaccination and Booster Dose Study of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200) in At-Risk Adults” NCT00869713 ↗1“Rift Valley Fever Vaccine, Inactivated, Dried (TSI GSD 200) will be administered in 1.0-mL doses SQ in the upper outer aspect of the arm.” NCT03609398 ↗ |
| Modality | Vaccine | “Rift Valley Fever (RVF) Vaccine, Inactivated” NCT00584194 ↗ |
| Route | Subcutaneous | “Subcutaneous 1.0-ml booster doses” NCT00584194 ↗ |